Evidence map›Paper›PMID 40909641›Full record

ArticlebioRxiv : the preprint server for biology2025

Peripheral immune patterns enable robust cross-platform prediction of ALS onset and progression.

Luvna Dhawka, Baggio A Evangelista, Omeed K Arooji, Marie A Iannone, Kyle Pellegrino, Rebecca Traub, Xiaoyan Li, Richard Bedlack, Rick B Meeker, Todd J Cohen and 1 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luvna DhawkaDepartment of Computer Science and Computational Medicine Program, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7666-3060
Baggio A EvangelistaDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-4166-3068
Omeed K AroojiDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Marie A IannoneLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Kyle PellegrinoDepartment of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Rebecca TraubDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Xiaoyan LiDepartment of Neurology, Duke University Medical Center, Durham, North Carolina, USA.
Richard BedlackDepartment of Neurology, Duke University Medical Center, Durham, North Carolina, USA.
Rick B MeekerDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Todd J CohenDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Natalie StanleyDepartment of Computer Science and Computational Medicine Program, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Spatial signatures of brain health and vulnerability in aging and Alzheimer's diseaseR21AG084251 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COHEN, TODD JONATHAN, STANLEY, NATALIE M · 2024 to 2025
$414k
Automating the Discovery of Clinically-Relevant Intracellular Signaling Responses in Immune Cell-TypesR21AI171745 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI STANLEY, NATALIE M · 2023 to 2024
$400k
Investigation of the innate and adaptive immune responses to TDP-43 aggregates in Amyotrophic Lateral SclerosisF31NS122242 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EVANGELISTA, BAGGIO ANGELO · 2022 to 2023
$62k
NCI NIH HHS P30 CA016086NIAID NIH HHS R21 AI171745NIA NIH HHS R21 AG084251NINDS NIH HHS F31 NS122242
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) progression rates vary dramatically between patients, yet the basis of this heterogeneity remains elusive, with no prognostic biomarkers existing to guide clinical decisions or stratify patients for therapeutic trials. Here, we identify a network of coordinated immune cell types, which exhibit differential disruption across progression groups. Using mass cytometry (CyTOF) to profile 2.2 million immune cells from 35 ALS patients stratified by progression rate and 9 healthy controls, we find that the extent of immune dysfunction cannot be reflected by examining differences in individual cell type frequencies. In contrast, analyses of correlation patterns between cell types revealed distinct immune organization patterns, where coordination complexity varied with disease progression. Across all progression groups, we observed striking immune reorganization in natural killer (NK) cells and a major shift from B cell/basophil coordination hubs in healthy controls to neutrophil/T cell-dominated patterns in ALS. Having established coordinated immune patterns, we developed machine learning models to further improve our ability to stratify between disease and non-disease cohorts, achieving superior performance compared to models using cell frequencies alone. Central and effector memory (CM/EM) CD4+ T cell interactions emerged as top discriminative features for disease status, while plasmacytoid dendritic cell (pDC) relationships, especially their ratio with regulatory T cells (T-regs), distinguished progression rates, supporting T-reg-based therapeutic approaches. These findings reframe ALS as a disease of immune coordination breakdown, pointing towards cell-type specific therapeutics and biomarkers that may extend beyond ALS to other neurodegenerative diseases characterized by immune dysfunction.

Identifiers

PMID40909641
PMCPMC12407898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.